MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
2. Industry_Business Architects & Consolidators
Industry: By Region (Globally)
Industry: U.S.(United States)
Industry: West + Pacific Rim
*Industry: Southern California
CG Oncology, Inc. (NASDAQ:CGON)*
Organization & Developments: CG Oncology
Parents
CG Oncology, Inc. (NASDAQ:CGON)*
Children
*Developing its product cretostimogene for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer [NMIBC].
2024: CG Oncology Is Late Stage Looker For Life Science Investors_ seekingalpha.com
2024: CG Oncology Launches Major $204M IPO with Shares Priced at $28, Backed by Top Wall Street Banks
2024: CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene_ seekingalpha.com
2024: CG Oncology: Promising Data, But Looks Expensive
2024: CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality
2024: Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer
2025: A First Take On CG Oncology
Jumps
Finance & Acquisitions: CG Oncology
Key People: CG Oncology